JP7352551B2 - 光学活性な架橋型ピペリジン誘導体 - Google Patents

光学活性な架橋型ピペリジン誘導体 Download PDF

Info

Publication number
JP7352551B2
JP7352551B2 JP2020535836A JP2020535836A JP7352551B2 JP 7352551 B2 JP7352551 B2 JP 7352551B2 JP 2020535836 A JP2020535836 A JP 2020535836A JP 2020535836 A JP2020535836 A JP 2020535836A JP 7352551 B2 JP7352551 B2 JP 7352551B2
Authority
JP
Japan
Prior art keywords
azabicyclo
alkyl
thieno
diazaspiro
trifluoroethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020535836A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020032105A5 (https=
JPWO2020032105A1 (ja
Inventor
正児 上岡
尚明 島田
仁志 坂
一人 山崎
晶彦 荒川
亘 広瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2020032105A1 publication Critical patent/JPWO2020032105A1/ja
Publication of JPWO2020032105A5 publication Critical patent/JPWO2020032105A5/ja
Application granted granted Critical
Publication of JP7352551B2 publication Critical patent/JP7352551B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2020535836A 2018-08-08 2019-08-07 光学活性な架橋型ピペリジン誘導体 Active JP7352551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018149547 2018-08-08
JP2018149547 2018-08-08
PCT/JP2019/031132 WO2020032105A1 (ja) 2018-08-08 2019-08-07 光学活性な架橋型ピペリジン誘導体

Publications (3)

Publication Number Publication Date
JPWO2020032105A1 JPWO2020032105A1 (ja) 2021-08-12
JPWO2020032105A5 JPWO2020032105A5 (https=) 2022-08-16
JP7352551B2 true JP7352551B2 (ja) 2023-09-28

Family

ID=69414766

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020535836A Active JP7352551B2 (ja) 2018-08-08 2019-08-07 光学活性な架橋型ピペリジン誘導体

Country Status (7)

Country Link
US (1) US20210198283A1 (https=)
EP (1) EP3835304B1 (https=)
JP (1) JP7352551B2 (https=)
CN (1) CN112771055B (https=)
CA (1) CA3108449A1 (https=)
ES (1) ES2991898T3 (https=)
WO (1) WO2020032105A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7618567B2 (ja) * 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性２級アミン誘導体
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
IL313033A (en) * 2021-12-03 2024-07-01 Bionova Pharmaceuticals Shanghai Ltd Carbonyl substituted diazaspiro compounds and its use
CN116693546B (zh) * 2022-01-28 2025-06-27 成都先导药物开发股份有限公司 Menin抑制剂及其用途
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
WO2025023321A1 (en) * 2023-07-27 2025-01-30 Sumitomo Pharma Co., Ltd. Process for preparing optically-active azabicyclo ring derivative, and intermediate for its production

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2017112768A1 (en) 2015-12-22 2017-06-29 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018050684A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
WO2018050686A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US11325921B2 (en) * 2018-03-30 2022-05-10 Sumitomo Dainippon Pharma Co., Ltd. Optically active crosslinked cyclic secondary amine derivative
KR102779601B1 (ko) * 2018-08-27 2025-03-12 스미토모 파마 가부시키가이샤 광학 활성인 아자비시클로환 유도체

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2017112768A1 (en) 2015-12-22 2017-06-29 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018050684A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
WO2018050686A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction

Also Published As

Publication number Publication date
EP3835304A4 (en) 2022-06-08
WO2020032105A1 (ja) 2020-02-13
EP3835304A1 (en) 2021-06-16
ES2991898T3 (es) 2024-12-05
CN112771055A (zh) 2021-05-07
CA3108449A1 (en) 2020-02-13
JPWO2020032105A1 (ja) 2021-08-12
CN112771055B (zh) 2023-10-20
EP3835304B1 (en) 2024-10-09
US20210198283A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7614262B2 (ja) 光学活性なアザビシクロ環誘導体
JP7352551B2 (ja) 光学活性な架橋型ピペリジン誘導体
JP7239562B2 (ja) 光学活性な架橋型環状２級アミン誘導体
JP7618567B2 (ja) 架橋型光学活性２級アミン誘導体
US10815241B2 (en) Optically active azabicyclo ring derivative
JP7454520B2 (ja) 光学活性なアザビシクロ環誘導体からなる医薬
HK40053381A (en) Optically active bridged piperidine derivative
HK40053381B (en) Optically active bridged piperidine derivative
HK40055661A (en) Optically active azabicyclic derivative
HK40043242A (en) Optically active crosslinked cyclic secondary amine derivative
EA041780B1 (ru) Оптически активное азабициклическое производное

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230915

R150 Certificate of patent or registration of utility model

Ref document number: 7352551

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150